礼来（LLY）在夜盘交易时段大涨5.12%，表现强劲。
消息面上，礼来宣布其用于治疗慢性淋巴细胞白血病的新药Jaypirca获得了欧洲药品管理局人用药品委员会的积极推荐，预计欧盟将在未来一至两个月内做出正式批准裁决。同时，公司另一款新药Onswik也获得了欧盟药监机构的正面上市推荐。此外，华尔街投行Leerink Partners将礼来的目标股价从1119美元上调至1232美元，并维持“跑赢大市”评级。这些多重利好消息共同提振了市场信心，推动了股价上涨。
礼来（LLY）在夜盘交易时段大涨5.12%，表现强劲。
消息面上，礼来宣布其用于治疗慢性淋巴细胞白血病的新药Jaypirca获得了欧洲药品管理局人用药品委员会的积极推荐，预计欧盟将在未来一至两个月内做出正式批准裁决。同时，公司另一款新药Onswik也获得了欧盟药监机构的正面上市推荐。此外，华尔街投行Leerink Partners将礼来的目标股价从1119美元上调至1232美元，并维持“跑赢大市”评级。这些多重利好消息共同提振了市场信心，推动了股价上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.